Patent Baristas

In a follow-up to my discussion on the Alza case, it is important to note that the U.S. Supreme Court agreed to review an appeal of a key patent case that could set a standard for when an invention is obvious. The Court has taken up the appeal by KSR International Inc., a Canadian manufacturer […]

I will be attending the BIO Mid-America VentureForum on September 26-27 in Cleveland, OH. The VentureForum, co-hosted by Omeris, is the Midwest’s largest annual event for bioscience and medical device product and platform companies from across the country. Approximately 75 companies seeking seed, early-and late-stage funding will make presentations. If you will be attending the […]

Alza Corp. appealed a district court’s finding of noninfringement and invalidity of claims 1-3, 11, 13 and 14 of U.S. Patent No. 6,124,355 for a generic version of the once-a-day extended release formulation of the anti-incontinence drug oxybutynin, which Alza has been marketing as Ditropan XL®. Alza had sued after Mylan and Impax filed ANDAs […]

A jury unanimously found that Abbott Laboratories willfully infringed Innogenetics’ U.S. Patent No. 5,846,704, which covers a method of genotyping the Hepatitis C Virus (“HCV”) using probes targeting sequences from the 5′ untranslated region of HCV. Hepatitis C viruses (HCV) are a family of positive-stranded, enveloped RNA viruses causing the majority of non-A, non-B (NANB) […]

The Boston Globe ran an article about Ohio Governor Bob Taft traveling to Boston looking to attract a few more companies — or at least their new or expanded facilities — for Ohio. On the heels of the recent acquisitions by Cincinnati’s Procter & Gamble Co. and Federated Department Stores of Boston’s Gillette Co. and […]

In another update to the preliminary injunction issued August 29 in the Plavix case, the cheeky Apotex has filed an appeal with the Court of Appeals for the Federal Circuit against the preliminary injunction preventing the drug company from selling a generic version of the heart drug Plavix. The request came a day after a […]

I don’t know what it is about wikis but there seems to be a wikification of the patent world. After the U.S. Patent and Trademark Office put out a draft Five Year Strategic Plan outlining their intention to develop a “peer review mechanism” that would enlist volunteers from the public to weigh in on applications, […]

On April 20, 2006, Amgen filed a lawsuit against Ariad in the U.S. District Court for the District of Delaware seeking a declaratory judgment that each of the claims contained in U.S. Patent No. 6,410,516, covering methods of treating human disease by regulating NF-κβ cell-signaling activity, are invalid and that Amgen has not infringed any […]